Indee Labs Status
The company received AUD 500,000 of grant funding from NSW State Government on August 8, 2018.
Developer of gene delivery hardware designed to unlock gene-modified cell therapy for the masses. The company's hardware is based on microfluidic technology that uses microfluidic vortex shedding to enable fast processing of small and large volumes of human primary immune cells and it can achieve high yield with a simple workflow and does not change human primary immune cell activation or exhaustion profiles, enabling efficient development and scalable manufacturing of gene-modified cell therapies.
Year Founded
2015
Employees
9
RevenueFY 2018
$310 K
General Information
-
Website
-
Business Status
Generating Revenue/Not Profitable
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Indee Labs News and Updates
MUSC immunology researcher receives SBIR grant to push boundaries of regulatory T-cell therapy
Mirage News | August 22, 2022
GenScript to Host 2nd Annual Gene & Cell Engineering Virtual Summit
PR Newswire | July 26, 2022
Indee Labs Awarded Contract from the National Cancer Institute
Business Wire | September 22, 2020
Australian government awards funding to Indee Labs for microfluidic chip development - BioPharma
BioPharma-Reporter.com | September 5, 2018
Indee Labs's Feed
Indee Labs's Verticals
Indee Labs Primary Industry Sector / Group / Code
Indee Labs's Trends
Indee Labs Metrics
Twitter Followers
Headquarters
-
HQ Address Line 1Bonneville Labs
-
HQ Address Line 2626 Bancroft Way, Suite A
-
HQ CityBerkeley
-
HQ State/ProvinceCalifornia
-
HQ Post Code94710
-
HQ CountryUnited States
Add a review